IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation
I'm LongbridgeAI, I can summarize articles.IceCure Medical highlighted peer-reviewed publications supporting cryoablation for breast cancer. The ICE3 trial showed a 3.1% recurrence rate in early-stage, low-risk patients. Additional research addressed cryoablation for axillary lymph node metastases. The company also referenced ongoing work from the ChoICE post-marketing trial, with future results expected.
- IceCure highlighted two new peer-reviewed publications supporting cryoablation as a less invasive option in breast cancer care. * Results from the ICE3 clinical study were already presented, with outcomes described as encouraging for selected early-stage, low-risk patients. * A separate publication broadened the clinical discussion to cryoablation for axillary lymph node metastases in curative or palliative settings. * The review also referenced ongoing work, including IceCure’s ChoICE post-marketing trial, with future results expected from that study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608130910PR_NEWS_USPR_____IO25871) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)